文献速递炎症性肠病

维得利珠单抗在新生儿中的清除、感染易感性及发育里程碑:前瞻性多中心人群队列研究

Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-09-02

该前瞻性多中心队列研究纳入2016-2020年丹麦和加拿大12家医院的50例维得利珠单抗暴露妊娠的炎症性肠病孕妇,评估新生儿脐带血药物水平、出生后清除速率、感染风险及1岁内发育里程碑。结果显示新生儿出生时药物中位比值为0.44,平均清除时间3.8个月,6月龄时均未检出药物;12月龄发育里程碑正常或高于平均水平,感染风险未增加。结论认为宫内暴露后新生儿清除迅速,孕期持续使用维得利珠单抗安全。

要点

  • 新生儿出生时维得利珠单抗中位比值为0.44,平均3.8个月清除,6月龄时均未检出。
  • 12月龄发育里程碑正常或高于平均水平,未发现感染风险增加。
  • 孕期持续使用维得利珠单抗未增加不良妊娠结局风险,无先天性畸形。

核心结论

  • 宫内暴露后新生儿维得利珠单抗清除迅速,6月龄时均未检出。
  • 婴儿维得利珠单抗水平与1岁内感染风险无关。
  • 孕期持续使用维得利珠单抗是安全的。

研究设计与样本

  • 前瞻性多中心人群队列研究,2016-2020年从丹麦和加拿大12家医院招募维得利珠单抗治疗的炎症性肠病孕妇。
  • 共50例维得利珠单抗暴露妊娠,收集人口学资料,用ASQ-3评估婴儿发育里程碑。
  • 分娩时及婴儿每3个月检测维得利珠单抗水平直至清除,采用非线性回归分析估计清除率。

主要发现

  • 50例暴露妊娠中43例(86%)活产,7例(14%)流产,无先天性畸形,不良妊娠结局风险低。
  • 新生儿出生时婴儿与母亲维得利珠单抗中位比值为0.44(95%CI 0.32-0.56)。
  • 婴儿维得利珠单抗平均清除时间为3.8个月(95%CI 3.1-4.4),6月龄时均未检出。
  • 12月龄发育里程碑正常或高于平均水平。
  • 妊娠晚期维得利珠单抗暴露(RR 0.54,95%CI 0.28-1.03)或联合硫嘌呤治疗(RR 1.29,95%CI 0.60-2.77)均未增加子代感染风险。

临床怎么用

  • 孕期可继续使用维得利珠单抗,无需因担心新生儿感染或发育问题而停药。
  • 新生儿出生后维得利珠单抗清除迅速,6月龄时药物已无残留,可按常规计划接种疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the consequences of intrauterine exposure to, and the post-natal clearance of, vedolizumab. AIMS: To investigate the levels of vedolizumab in umbilical cord blood of newborns and rates of clearance after birth, as well as how these correlated with maternal drug levels, risk of infection and developmental milestones during the first year of life METHODS: Vedolizumab-treated pregnant women with inflammatory bowel disease were prospectively recruited from 12 hospitals in Denmark and Canada in 2016-2020. Demographics were collected from medical records. Infant developmental milestones were evaluated by the Ages and Stages Questionnaire (ASQ-3). Vedolizumab levels were measured at delivery and, in infants, every third month until clearance. Non-linear regression analysis was applied to estimate clearance. RESULTS: In 50 vedolizumab-exposed pregnancies, we observed 43 (86%) live births, seven (14%) miscarriages, no congenital malformations and low risk of adverse pregnancy outcomes. Median infant:mother vedolizumab ratio at birth was 0.44 (95% confidence interval [CI], 0.32-0.56). The mean time to vedolizumab clearance in infants was 3.8 months (95% CI, 3.1-4.4). No infant had detectable levels of vedolizumab at 6 months of age. Developmental milestones at 12 months were normal or above average. Neither vedolizumab exposure in the third trimester (RR 0.54, 95% CI, 0.28-1.03) nor combination therapy with thiopurines (RR 1.29, 95% CI, 0.60-2.77) seemed to increase the risk of infections in the offspring. CONCLUSIONS: Neonatal vedolizumab clearance following intrauterine exposure is rapid. Infant vedolizumab levels did not correlate with the risk of infections during the first year of life. Continuation of vedolizumab throughout pregnancy is safe.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Julsgaard M, Baumgart DC, Baunwall SMD, et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021. PMID: 34472644. doi:10.1111/apt.16593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。